in this issue
Regions :: Western Europe :: Sweden
Swedish drugmaker Meda rejects Mylan's bid offer
10:59 AM MDT | April 28, 2014 | Natasha Alperowicz
In the latest wave of M&A frenzy in the pharma industry, Meda (Solna, Sweden) today rejected a revised bid offer by Mylan, the largest generic-drug company in the United States. “The board hereby confirms that it has been contacted by Mylan regarding a revised, nonbinding, indicative interest to combine the two businesses. The board has convened and has decided to reject the proposal. All contacts between Meda and Mylan have been terminated without further actions. The board’s decision is based on a strong belief in the continued potential of Meda...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee